Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 12/20 | 0.43 |
| ▸ | AURKA | O14965 | 11/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.43 |
| ▸ | PLK2 | Q9NYY3 | 6/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | NEK2 | P51955 | 1/20 | 0.35 |
| ▸ | NEK5 | Q6P3R8 | 1/20 | 0.35 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573049 | 0.86 | CDK1 (0.46) | CDK1AURKACCNB1CYP3A4CYP2C9 | |
| SCHEMBL1356204 | 0.81 | PLK2 (0.45) | CDK1AURKACCNB1PLK2NEK2 | |
| SCHEMBL1355521 | 0.81 | AURKA (0.46) | CDK1AURKACCNB1PLK2CYP3A4 | |
| SCHEMBL3581811 | 0.81 | CDK1 (0.44) | CDK1AURKACCNB1CYP3A4CYP2C9 | |
| SCHEMBL1355558 | 0.80 | CDK1 (0.48) | CDK1AURKACCNB1CYP3A4CYP2C9 | |
| SCHEMBL1355345 | 0.79 | EGFR (0.51) | CDK1AURKACCNB1FGFR4 | |
| SCHEMBL3585804 | 0.78 | CDK1 (0.46) | CDK1AURKACCNB1CYP3A4CYP2C9 | |
| SCHEMBL1355910 | 0.76 | FGFR4 (0.50) | CDK1AURKACCNB1CYP3A4CYP2C9 | |
| SCHEMBL3862278 | 0.75 | AURKA (0.48) | CDK1AURKACCNB1CYP3A4CYP2C9 | |
| SCHEMBL3591861 | 0.75 | AURKA (0.54) | CDK1AURKACCNB1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | claimed |
| EP-2108020-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | claimed |
| WO-2008094602-A2 | 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | claimed |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249067-A1 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | CDK1 3/4885AURKA 9/4885CCNB1 12/4885 |
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | CDK1 1/4885AURKA 10/4885CCNB1 17/4885 |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | CDK1 3/4885AURKA 9/4885CCNB1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.